Curetis Completes Development of Unyvero Cartridge for Intra-Abdominal Infections – Highly multiplexed panel covers up to 112 diagnostic targets – Third new panel developed within one […]
Curetis Announces Positive Top Line Data from U.S. FDA Trial – Primary endpoint for Unyvero LRT product for lower respiratory tract infections shows overall weighted average […]
Curetis Acquires Patents and Rights to Genetic Antibiotic Resistance and Susceptibility (GEAR) Database and Know-How from Siemens – Agreement gives Curetis worldwide rights to database and […]
Curetis to Launch Next Generation CE-IVD Unyvero Implant and Tissue Infection Application Cartridge – Launch follows successful completion of CE Performance Evaluation Study – ITI now […]
Curetis Appoints Christopher M. Bernard as Chief Executive Officer of Newly-Formed U.S. Subsidiary – Former Chief Commercial Officer of Epic Sciences brings valuable experience in sales, […]
Curetis Completes Sample Enrollment in Unyvero U.S. FDA Trial in Lower Respiratory Tract Infections – Last patient enrolled in prospective arm of IVD trial – More […]
Jun 16, 2016 | NEW YORK (GenomeWeb) – Curetis said today that it has received the CE-IVD mark for its Unyvero BCU Blood Culture Application Cartridge […]
Curetis Publishes First Quarter 2016 Business and Financial Update – Worldwide commercial expansion and US FDA trial on track – Installed base of Unyvero Analyzers increased […]